지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.6
- 수록면
- 149 - 157 (9page)
- DOI
- https://doi.org/10.3904/kjm.2024.99.3.149
이용수
초록· 키워드
오류제보하기
Background/Aims: Carbapenems are recommended for treating bacteremia caused by extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae (ESBL-E). However, this has resulted in a significant rise in the utilization of carbapenems in cases of ESBL-E infection. We evaluated the clinical outcomes of patients with ESBL-E bacteremia treated with non-carbapenem antimicrobials.
Methods: We conducted a retrospective case-control study of a cohort of patients with documented ESBL-E bacteremia from January 2021 to December 2021. The patients were divided into two groups according to whether they received non-carbapenem or carbapenem therapy. The rates of treatment failure, 30-day mortality and microbiologic failure, and the durations of hospitalization and of antimicrobial therapy were compared between the two groups. Antimicrobial susceptibility testing and phenotypic identification of ESBL-E were performed using the Vitek 2 system.
Results: Of 118 patients with ESBL-E bacteremia, 54 received non-carbapenem drugs (non-carbapenem group [NCG]) and 64 received carbapenems (carbapenem group [CG]). Treatment failure at 30 days occurred in 16.7% of the patients in the NCG and in 18.8% in the CG (p = 0.65). The 30-day mortality rate was 14.8% in the NCG and 17.2% in the CG (p = 0.63). Extra-urinary tract infection and prior antimicrobial therapy within 30 days were risk factors for treatment failure in patients with ESBL-E bacteremia. The clinical outcomes did not differ significantly between the two groups, challenging the prevailing preference for carbapenems in the treatment of ESBL-E bacteremia.
Conclusions: Non-carbapenem antimicrobials such as piperacillin/tazobactam are recommended for patients with mild ESBL-E bacteremia in South Korea.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Clinical Outcomes of Non-carbapenem Treatment for Urinary Tract Infections Caused by Extended-spectrum β-lactamase-producing Escherichia coli
Childhood Kidney Diseases
2021 .01
-
Characteristics and Clinical Outcomes of Extended-Spectrum beta-lactamase-producing Klebsiella pneumoniae Bacteremia in Cancer Patients
Infection and Chemotherapy
2020 .01
-
Escherichia coli와 Klebsiella pneumoniae 균혈증의 베타락탐 내성 추세와 세포탁심 감수성 ESBL 생성균주의 임상적 특징
의료관련감염관리
2023 .06
-
Changes of Antimicrobial Resistance Causing Infections Following Transrectal Prostate Biopsy: Analysis of 10-Year Data
Urogenital Tract Infection
2021 .12
-
Changing Epidemiology of Extended Spectrum Beta-Lactamases Pathogen of Urinary Tract
Urogenital Tract Infection
2015 .01
-
Surveillance of Extended-Spectrum β-Lactamase-producing Enterobacteriaceae Carriage in a Japanese Intensive Care Unit: a Retrospective Analysis
Acute and Critical Care
2016 .01
-
Are Community-Based Hospitals Safe from Carbapenem-Resistant Enterobacteriaceae in Korea?
Infection and Chemotherapy
2016 .01
-
Extended-spectrum β-lactamase 를 생산하는 Enterobacteriaceae 요로감염에서 카바페넴 이외의 항생제 사용 가능성에 대한 고찰
의료관련감염관리
2016 .01
-
Prevalence and Molecular Epidemiology of Extended-Spectrum-β-Lactamase (ESBL)-Producing Escherichia coli From Multiple Sectors of the Swine Industry in Korea: A Korean Nationwide Monitoring Program for a One Health Approach to Combat Antimicrobial Resistance
Annals of Laboratory Medicine
2021 .01
-
지역사회 기질확장성 베타락타메이즈 생성 대장균의 확산 상황에서 집단발생이 없는 중환자실 내원환자의 적극적 감염감시 배양의 유용성
Annals of Clinical Microbiology
2018 .01
-
Antimicrobial Susceptibilities of Enterobacteriaceae in Community-Acquired Urinary Tract Infections during a 5-year Period: A Single Hospital Study in Korea
Infection and Chemotherapy
2017 .01
-
Active Surveillance for Carbapenem-resistant Enterobacteriaceae at a Single Center for Four Years
Annals of Laboratory Medicine
2022 .05
-
카바페넴계 항생제 장기사용 단축을 위한 중재효과 분석
의료관련감염관리
2023 .06
-
Failure of Ciprofloxacin Therapy in the Treatment of Community-Acquired Acute Pyelonephritis caused by In-Vitro Susceptible Escherichia coli Strain Producing CTX-Type Extended-Spectrum β-Lactamase
Infection and Chemotherapy
2018 .01
-
응급실을 방문한 광범위베타락탐분해효소 양성 대장균 요로감염 환자의 임상적 특징 및 위험인자
대한소아응급의학회지
2020 .01
-
Quantitative Evaluation of the Economic Impact of Antimicrobial Resistance on the Treatment of Community-Acquired Acute Pyelonephritis in Korea
Infection and Chemotherapy
2022 .09
-
Extended-spectrum ß-Lactamase-producing Enterobacteriaceae as a Common Cause of Urinary Tract Infections in Sri Lanka
Infection and Chemotherapy
2016 .01
-
Challenges of Carbapenem-resistant Pseudomonas aeruginosa in Infection Control and Antibiotic Management
Annals of Laboratory Medicine
2024 .01
-
Extended-Spectrum β-Lactamase 생성 균주와비생성 균주에 의한 지역사회 획득 요로 감염 비교
Pediatric Infection and Vaccine
2015 .01
-
Clinical and Therapeutic Implications of Aeromonas Bacteremia: 14 Years Nation-Wide Experiences in Korea
Infection and Chemotherapy
2016 .12
최근 본 자료
댓글(0)
0